Skip to content
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Resources
2024 Saving Report
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
Digital Campaigns
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
Resources
2024 Saving Report
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
Digital Campaigns
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
Advocacy
Issues Overview
State Advocacy
GDUFA/BsUFA User Fees
Action Center
Events
Access! 2025
GRx+Biosims 2025
Press Releases
JOIN
Advocacy
Issues Overview
State Advocacy
GDUFA/BsUFA User Fees
Action Center
Events
Access! 2025
GRx+Biosims 2025
Press Releases
JOIN
Home
Resources
Reports
Reports
Reports
August 24, 2018
AAM
REMS and Restricted Distribution Programs
Reports
January 29, 2018
AAM
Poll Results: California Proposed Drug Pricing Law (SB 17)
Reports
January 29, 2018
AAM
2016 Annual Report
Reports
October 20, 2017
AAM
AAM White Paper: Renting Tribal Immunity to Evade IPR Review of Pharmaceutical Patents
Load More
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Resources
2024 Saving Report
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
Digital Campaigns
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
Advocacy
Issues Overview
State Advocacy
GDUFA/BsUFA User Fees
Action Center
Events
Access! 2025
GRx+Biosims 2025
Press Releases
JOIN